...less...
Allergy plays a key role in asthma, both by leading to the onset of the disease and by triggering exacerbations. Learn about the key action steps clinicians should consider in the diagnosis and management of patients with respiratory symptoms suggesting asthma.
As a pulmonologist you tend to see a more difficult patient with asthma who has other co-morbidities that make their disease more complicated and difficult to control. In this slide presentation, we discuss the role of allergy in a pulmonologist’s practice. We hope you find this presentation helpful in the treatment of your patients.
Target Audience: Pulmonologists
Presented by Dr. Donald Rollins Associate Professor of Medicine, Pulmonary Division, Department of Medicine, National Jewish Health
Need to view these files and you don't have PowerPoint?
Download the PowerPoint viewer for Windows computers.
Apple computer users can open this file with KeyNote.
The following PowerPoint presentation presents points of clinical consensus arrived at by participants in a closed meeting held at National Jewish Health in Denver, Colorado, on October 8, 2009, on the role of intranasal antihistamines in the management of allergic rhinitis. The following represents a summary of the experts' presentations, discussions and recommendations.The Consensus Panel held at National Jewish Health focused on the topic - Rethinking the Treatment of Allergic Rhinitis: The Role of Intranasal Antihistamines: 'Me Too Drugs" or a Novel Class?
The project was chaired by Dr. Rohit Katial, Professor of Medicine, Program Director, Allergy and Immunology, and Director, Weinberg Clinical Research Unit, National Jewish Health. The objectives of this symposium were to: 1) describe the patient's perspective of the burden of allergic rhinitis and unmet needs, 2) discuss the new place of intranasal antihistamines as first-line therapies and compare and contrast this class of medication to the traditionally available medications, 3) discuss the potential for intranasal antihistamines to provide relief superior to second-generation oral antihistamines, and 4) explain how intranasal antihistamines fit into the latest guidelines.
National Jewish Health was honored to have the preeminent leaders in the field contributing to a supplement based on this symposium, including: Rohit Katial, MD; Phil Lieberman, MD; Eli O. Meltzer, MD; Paul H. Ratner, MD; William E. Berger, MD; Michael A. Kaliner, MD; Charles J. Siegel, MD; Don A. Bukstein, MD; Carman A. Ciervo, DO; and Bradley Marple, MD. The supplement will be published in the Annals of Allergy, Asthma, & Immunology in the Fall of 2010.
In addition to providing a historical perspective of allergic rhinitis, an overview of histamine mechanism of action, and reviews of current allergic rhinitis therapies, the monograph will also include updated suggested approaches to patient management.
Dr. Katial has also prepared a slide kit which covers the same topic and sections. This information is available for your presentation use. If you have questions contact the Office of Professional Education at 800.444.2305 or 800.423.8891, extension 1000.
Disclosure: The Consensus Panel, and the resulting Consensus Statement and journal supplement were funded through an educational grant from Meda Pharmaceuticals Inc. The commercial supporter was not involved in the content development.
Please Download the slide kit.
Patients seen in the clinican’s office with symptoms suggesting asthma likely have allergy playing a role in their illness. While the “hygiene hypothesis” suggests that asthma risk is decreased with childhood exposure to certain environmental antigens, the IgE-mediated allergic response is both a progenitor and sustainer of airway inflammation leading to acute and chronic asthma symptoms in both children and adults. New National Asthma Education and Prevention Program (NAEPP) guidelines encourage evaluation of our patients with persistent asthmatic symptoms with allergy testing to help identify factors responsible for aggravating and fomenting underlying airway inflammation. Immunoassay testing for the presence of antigen-specific IgE antibodies in asthma patients is now available in the office or hospital setting and should play an important diagnostic role in patient evaluation. In addition to the use of inhaled corticosteroids, the confirmation of allergy by in vitro testing may support the use of specific medications to reduce mast cell mediator cytokine release or cell signaling in the allergic cascade (cromolyn, nedocrimil, zyleuton, monteleukast), or use of anti-IgE therapy (omalizumab). Most importantly, knowledge of a patient’s allergic predisposition, or atopy, encourages the physician to stress preventative environmental exposure reduction and provide the patient with practical advice on how to accomplish this in their home and lifestyle as a complementary and important part of their treatment program.
To read the rest of the Newsletter please click here.
80% of smokers want to quit yet less than 5% are successful on their own. Join us for this symposium and learn how you can improve the health outcomes of your patients.
646,000 adults in the state of Colorado smoke; are some of them your patients? 80% of smokers want to quit, yet less than 5% are successful on their own.
Please join us for a half-day educational symposium in Denver, CO and learn how you can improve the health outcomes of your patients.
Register Now!
8:00 am — 1:00 pm Continental breakfast and lunch included
Family Medicine and Internal Medicine Physicians, Pulmonologists, Physician Assistants, Nurse Practitioners, Registered Nurses, Pharmacists and other allied health professionals.
Barry Make, MD Co-Director COPD Program Director, Pulmonary Rehab and Respiratory Care Professor of Medicine National Jewish Health
Scott Van Da Walker, MSN, FNP-C COPD Clinical Program Coordinator, National Jewish Health
There is no cost for this event. Seating is limited.
These symposia are non-certified, educational outreach programs.
National Jewish Health reserves the right to make changes to this event without notice. We will contact registrants if the course has been canceled or moved to another date.
The following White Paper presents points of clinical consensus arrived at by participants in a closed meeting held at National Jewish Health in Denver, Colorado. The meeting took place on July 20, 2009. The group of clinicians and researchers, all leaders in the field of asthma, met to discuss the utility of FENO in the diagnosis and management of asthma. The following represents a summary of their presentations, discussions and recommendations.This meeting was funded by an unrestricted educational grant from Aerocrine.
Moderator: David Tinkelman, MD, National Jewish Health, Denver, CO
